InvestorsHub Logo
Followers 56
Posts 1134
Boards Moderated 1
Alias Born 01/13/2017

Re: FELLER post# 52208

Tuesday, 02/21/2017 9:23:44 AM

Tuesday, February 21, 2017 9:23:44 AM

Post# of 203914
I love the comparisons to GWPH, but I own some GWPH (very conflicted about that BTW) and I've done my DD. GWPH looks expensive, but Goldman Sachs has a price target of $189 and a buyout target price of $349. I'm gonna sell my GWPH because of what they are doing, but for those who want to make this comparison know that GWPH is deemed as undervalued right now too.

Goldman Sachs initiated coverage on GW Pharma (NASDAQ: GWPH) with a Buy rating and a price target of $189, implying upside of 42%. Analyst Salveen Richter sees potential for $1.6 billion in worldwide sales for lead asset Epidiolex. In an M&A scenario the stock could be worth $349, the firm said.



http://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Sees+42%25+Upside+in+GW+Pharma+(GWPH)+and+Initiates+Coverage+at+Buy/12113118.html

Know What You Own. My posts should not be construed as investment advice.